BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 32373970)

  • 1. METTL3 promotes the progression of nasopharyngeal carcinoma through mediating M6A modification of EZH2.
    Meng QZ; Cong CH; Li XJ; Zhu F; Zhao X; Chen FW
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4328-4336. PubMed ID: 32373970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The m6A methyltransferase METTL3 aggravates the progression of nasopharyngeal carcinoma through inducing EMT by m6A-modified Snail mRNA.
    Yu X; Zhao H; Cao Z
    Minerva Med; 2022 Apr; 113(2):309-314. PubMed ID: 32512975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simvastatin is beneficial to lung cancer progression by inducing METTL3-induced m6A modification on EZH2 mRNA.
    Chen WW; Qi JW; Hang Y; Wu JX; Zhou XX; Chen JZ; Wang J; Wang HH
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4263-4270. PubMed ID: 32373962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long non-coding RNA ANCR promotes progression of NSCLC by inhibiting E-Ca expression.
    Zhou T; Fang JJ; Zhou YX; Li ZP; Jiang L; Han WW; Zhu ZH
    Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1250-1257. PubMed ID: 32096155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. METTL3 Accelerates Breast Cancer Progression via Regulating EZH2 m
    Hu S; Song Y; Zhou Y; Jiao Y; Li G
    J Healthc Eng; 2022; 2022():5794422. PubMed ID: 35392146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long non-coding RNA GClnc1 promotes progression of colorectal cancer by inhibiting p53 signaling pathway.
    Dong YX; Pang ZG; Zhang JC; Hu JQ; Wang LY
    Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5705-5713. PubMed ID: 31298323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The m6A Methyltransferase METTL3-Mediated N6-Methyladenosine Modification of DEK mRNA to Promote Gastric Cancer Cell Growth and Metastasis.
    Zhang HM; Qi FF; Wang J; Duan YY; Zhao LL; Wang YD; Zhang TC; Liao XH
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Function of AXL and molecular mechanisms in regulation of nasopharyngeal carcinoma.
    Zhou K; Zhao J; Xu H; Yan X; Liu W; Jiang X; Ren C
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Jun; 47(6):685-697. PubMed ID: 35837768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP.
    Ma Z; Li Q; Liu P; Dong W; Zuo Y
    Cell Biol Int; 2020 Dec; 44(12):2524-2531. PubMed ID: 32869897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. METTL3/IGF2BP2 axis affects the progression of colorectal cancer by regulating m6A modification of STAG3.
    Yi J; Peng F; Zhao J; Gong X
    Sci Rep; 2023 Oct; 13(1):17292. PubMed ID: 37828232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcription factor RELA promotes hepatocellular carcinoma progression by promoting the transcription of m6A modulator METTL3.
    Wu J; Wang W; Zheng Y; Deng W; Liu J
    Pathol Res Pract; 2024 Mar; 255():155168. PubMed ID: 38367599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-130-5p promotes invasion as well as migration of lung adenocarcinoma cells by targeting the EZH2 signaling pathway.
    Zhang G; Wu YJ; Yan F
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(21):9480-9488. PubMed ID: 31773700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. METTL3-mediated m6A modification promotes processing and maturation of
    Gong Y; Jiang Q; Liu L; Liao Q; Yu J; Xiang Z; Luo X
    Physiol Genomics; 2022 Sep; 54(9):337-349. PubMed ID: 35759451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. m6A methyltransferase METTL3 promotes the progression of prostate cancer via m6A-modified LEF1.
    Ma XX; Cao ZG; Zhao SL
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(7):3565-3571. PubMed ID: 32329830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA LINC00673 inhibits p53 expression by interacting with EZH2 and DNMT1 in papillary thyroid carcinoma.
    Meng XF; Zhao LY; Chu XF
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2075-2083. PubMed ID: 30915752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiRNA-506 presents multiple tumor suppressor activities by targeting EZH2 in nasopharyngeal carcinoma.
    Fan DC; Zhao YR; Qi H; Hou JX; Zhang TH
    Auris Nasus Larynx; 2020 Aug; 47(4):632-642. PubMed ID: 31932074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. METTL3-mediated N6-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer.
    Yue B; Song C; Yang L; Cui R; Cheng X; Zhang Z; Zhao G
    Mol Cancer; 2019 Oct; 18(1):142. PubMed ID: 31607270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulated METTL3 in nasopharyngeal carcinoma enhances the motility of cancer cells.
    Liu ZF; Yang J; Wei SP; Luo XG; Jiang QS; Chen T; Gong YQ
    Kaohsiung J Med Sci; 2020 Nov; 36(11):895-903. PubMed ID: 32668092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysregulated N6-methyladenosine methylation writer METTL3 contributes to the proliferation and migration of gastric cancer.
    Liu T; Yang S; Sui J; Xu SY; Cheng YP; Shen B; Zhang Y; Zhang XM; Yin LH; Pu YP; Liang GY
    J Cell Physiol; 2020 Jan; 235(1):548-562. PubMed ID: 31232471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA MSTO2P promotes proliferation and autophagy of lung cancer cells by up-regulating EZH2 expression.
    Wang LJ; Sun GZ; Chen YF
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3375-3382. PubMed ID: 31081092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.